Background: Cardiomyopathies in children are serious, continuously progressing myocardium diseases which are characterized by a variety of the causes, symptoms, implications, and high lethality. More than 400 genes that can cause hereditary heart and vessels diseases are described in scientific literature. The application of a high-performance method of massive parallel sequencing allows to conduct the investigation of genome extended targeted areas revealing the variants and analyzing them (bioinformatics) for pathogenicity.Aims: Identification of a genetic etiology of hereditary cardiomyopathies development in children’s population of the Russian Federation.Materials and methods: The research included 103 patients with various phenotypes of cardiomyopathies aged from 3 months up to 17 years 9 months who at the moment of examination were observed in the cardiology department and the department of recovery treatment with cardiovascular diseases in the NMRCCH. All patients were performed massive parallel sequencing analyzing the targeted areas of 404 genes which mutations lead to the development of heart and vessels hereditary diseases.Results: The diagnostic algorithm based on the method of a massive parallel sequencing was developed. 176 258 minor options were identified in the explored target areas of genome of 103 patients. An average number of the revealed nucleotide replacements different from the reference sequence was 1711. We observed that about 40% of all variants founded by our means were found in MYH7, MYBPC3, TTN, MYH6, SCN5A, DSC2 and TPM1 genes. Bioinformatics analysis allowed revealing 68 novel genome variants associated with cardiomyopathy development. The reliable association of carriage of pathogenic option in MYBPC3 gene with development of hypertrophic cardiomyopathy in the Russian children was found.Conclusions: The application of the offered algorithm allowed establishing laboratory diagnoses to 99 (96.1%) patients out from 103 investigated subjects including the syndromal and non-syndromal forms of heart and vessels hereditary diseases which showed a cardiomyopathy phenotype.
Aim. To analyze and demonstrate various phenotypes in patients with familial left ventricular noncompaction (LVNC). Materials and methods. In 2013 was created a multicenter registry of LVNC patients. On its basis 30 families with a familial LVNC were selected. Results. 30 LVNC families were selected from the register. From a total of 115 people (probands and relatives) in 71 (61.7%) LVNC was diagnosed (30 probands and 41 relatives with non-compact myocardial criteria). The most common type of remodeling in patients was the dilated type (DT) (n=30), the isolated LVNC with preserved ejection fraction (EF) was slightly less common (n=23), and the hypertrophic type (GT) was detected in 8 patients. 4 patients were diagnosed with the isolated LVNC with a reduced EF. 3 patients were with a combination of non-compact myocardium with congenital heart disease and with a combination of DT and GT (DT+GT). During the analysis of cases a combination of different phenotypes in the same family was observed. The largest number of families was diagnosed with a combination of DT and the isolated LVNC with preserved EF. The development of cardiovascular complications was associated with DT. Conclusion. Family cases of LVNC had different types of myocardial remodeling and variants of clinical course. In one family a combination of different types of left ventricular remodeling is possible. DT is associated with the most severe clinical manifestations. The clinical picture of the isolated LVNC with preserved EF, is the most favorable, but in rare cases, serious clinical manifestations were observed.
18 January 2023 in Cardiovascular Therapy and Prevention
Left ventricular non-compaction (LVNC) is a rare, genetically and phenotypically heterogeneous disease, which is often accompanied by diagnostic difficulties.Aim. To demonstrate several generations of a family with LVNC with various clinical and phenotypic manifestations of the disease (dilated and isolated types of LVNC) with an identified rs397516387 variant of the TPM1 gene.Material and methods. Based on the multicenter registry "Myocardial Non-compaction", a family with a familial form of LVNC was selected. Next generation sequencing (NGS) was performed on an Ion S5 system (Thermo Fisher Scientific, USA) using Ampliseq technology. Variant was verified using Sanger sequencing on an Applied Biosystem 3500 Genetic Analyzer (Thermo Fisher Scientific, USA). For clinical interpretation, variants in the genes associated with LVNC with a minor allele frequency <0,1% were selected in the gnomAD database (v2.1.1). Results. Variant rs397516387 was found in 5 family members, including the proband. Further examination revealed LVNC in 2 additional family members. The proband and the proband’s uncle had a dilated type of LVNC, and the proband’s mother had an isolated type.Conclusion. The paper presents several generations of a family with different phenotypic manifestations of LVNC and rs397516387 variant in the TPM1 gene. The beginning of genetic screening from a proband, a thorough collection of a family history and further detailed genetic screening of relatives led to the identification of rs397516387 variant in 4 more family members, which in turn made it possible to conduct an additional examination to confirm the diagnosis and prescribe timely drug therapy.
Background. Non-compaction cardiomyopathy is a group of genetically heterogeneous, poorly studied myocardial diseases with a variety of clinical manifestations (from asymptomatic course to progressive systolic dysfunction with symptoms of chronic heart failure, arrhythmias, and thromboembolic complications). Considering the variety of genetic disorders associated with the development of noncompaction cardiomyopathy, genetic verification of the diagnosis is important for determining the prognosis and conducting genetic counselling of families with cases of the disease.Description of the Clinical Case. The article presents two clinical observations of a severe course of non-compaction cardiomyopathy with remodeling of the heart cavities according to the dilated phenotype. In order to clarify the disease etiology, a molecular genetic study was conducted using the method of direct automatic sequencing with the analysis of targeted regions of 404 genes which mutations are described in hereditary diseases of the heart and blood vessels. After verifying the mutation (in the ACTC1 and MYBPC3 genes), we performed a search for the detected nucleotide substitution in the venous blood samples of parents and in one case — in the fetal DNA sample. The mode of inheritance has been determined; the probability of recurrence of the disease in siblings in subsequent pregnancies has been estimated.Conclusion. The description of clinical cases shows the importance of genetic verification of the diagnosis in patients with non-compaction cardiomyopathy for determining the disease prognosis and developing an algorithm for monitoring relatives of a proband.
31 January 2026 in L.O. Badalyan Neurological Journal
Introduction. Oxidative phosphorylation deficiency, type 10 is a rare variant of mitochondrial disease characterized by lactate acidosis, damage to the cardiovascular and central nervous systems. Given the variability of phenotype-genotypic correlations, a detailed description of the clinical picture of the disease is important for understanding possible variants of the course of the disease.Materials and methods. During a molecular genetic study of three hundred fourteen pediatric patients with a guiding diagnosis of hypertrophic cardiomyopathy, one patient with a deficiency of oxidative phosphorylation, type 10, was identified.Results. The analysis of the nature of the disease course during the period of dynamic follow-up (over 3 years) was carried out.Conclusion. Deficiency of oxidative phosphorylation, type 10, is a rare cause of the hypertrophic phenotype of cardiomyopathy. Isolated cases of this disease have been described in the literature, which makes the observation significant for a wide range of specialists (pediatricians, neurologists, cardiologists).Compliance with ethical standards. Voluntary informed consent was obtained from the patient’s legal representative for the publication of material related to the patient in Russian and foreign medical periodicals (dated October 1, 2024). Contribution:Shifova N.A. — concept and design of research, collection and processing of material, writing, editing;Gandaeva L.A. — editing;Globa O.V. — editing;Silnova I.V. — editing;Davydova Yu.I. — editing;Basargina E.Y. — editing;Savostyanov K.V. — the concept and design of the study.All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.Funding. The study had no sponsorship.Conflict of interest. The authors declare no conflict of interest.Received: August 18, 2025Accepted:September 30, 2025Published: January 31, 2026
8 February 2026 in Cardiovascular Therapy and Prevention
Aim. To compare echocardiographic parameters in patients with familial hypertrophic cardiomyopathy and confirmed variants in the MYH7 and MYBPC3 genes. Material and methods. This study included a comprehensive assessment of echocardiographic parameters in 48 patients with hypertrophic cardiomyopathy, including 14 men and 34 women, aged 18-77 years. Subjects were divided into two groups based on confirmed variants in the MYH7 and MYBPC3 genes. Results. Patients with a MYBPC3 gene variant had significantly larger right atrial size and left ventricular (LV) posterior wall thickness (p=0,42, p=0,002), while LV systolic function, assessed using the additional speckle tracking echocardiography, was significantly lower compared to patients with a variant in the MYH7 gene (p=0,021). Conclusion. Patients with a variant in the MYBPC3 gene showed significant changes in structural and functional echocardiography parameters, indicating a less favorable prognosis for this group of patients.